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Ida Surakka,1,6 Aarno Palotie,1,2,3,7,8 Markus Perola,1,5 Veikko Salomaa,5 Mark J. Daly,1,2,3,4
Samuli Ripatti,1,9 and Matti Pirinen1,9,10,*
Polygenic scores (PSs) are becoming a useful tool to identify individuals with high genetic risk for complex diseases, and several projects
are currently testing their utility for translational applications. It is also tempting to use PSs to assess whether genetic variation can
explain a part of the geographic distribution of a phenotype. However, it is not well known how the population genetic properties of
the training and target samples affect the geographic distribution of PSs. Here, we evaluate geographic differences, and related biases,
of PSs in Finland in a geographically well-defined sample of 2,376 individuals from the National FINRISK study. First, we detect
geographic differences in PSs for coronary artery disease (CAD), rheumatoid arthritis, schizophrenia, waist-hip ratio (WHR), body-
mass index (BMI), and height, but not for Crohn disease or ulcerative colitis. Second, we use height as a model trait to thoroughly assess
the possible population genetic biases in PSs and apply similar approaches to the other phenotypes. Most importantly, we detect
suspiciously large accumulations of geographic differences for CAD, WHR, BMI, and height, suggesting bias arising from the
population’s genetic structure rather than from a direct genotype-phenotype association. This work demonstrates how sensitive the
geographic patterns of current PSs are for small biases even within relatively homogeneous populations and provides simple tools to
identify such biases. A thorough understanding of the effects of population genetic structure on PSs is essential for translational appli-
cations of PSs.Introduction
Understanding the causes behind geographic health differ-
ences can help to optimally apply limited healthcare
resources and improve public health. Geographic health
differences can be partially explained by lifestyle and
environmental factors, but also by genetic differences
that affect health both through population-specific genetic
diseases, e.g., the Finnish Disease Heritage (see Web
Resources), and through variation in the polygenic
components of many complex diseases.1–3 In particular,
recent discoveries from genome-wide association studies
(GWASs)4 have enabled improved polygenic prediction
of complex diseases and traits and raised expectations for
their future translation to clinical use.5–8 It is an open ques-
tion to what extent the geographic distribution of pheno-
types could be explained by their polygenic predictions.
A standard way to estimate a polygenic score (PS) of an
individual is to select a set of independent variants identi-
fied by a GWAS, to weight the number of copies of each
variant by its estimate of effect size from the GWAS, and
to sum these quantities over the variants. PSs have turned
out to be a useful tool for identifying individuals at high
risk for many diseases, such as breast cancer,5 prostate
cancer,9 and Alzheimer disease.8 As an example, a PS for
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monogenic variant of familial hypercholesterolemia.7 At
the same time, two recent studies have raised concerns
about comparing PSs between populations with varying
demographic histories.10,11 Both studies showed that
when a PS was built on a GWAS conducted in European
populations and then applied to populations from Africa
or East Asia, the differences in the PS were inconsistent
with the actual phenotypic differences between the popu-
lations. Exact reasons for this inconsistency are unclear,
but it has been speculated that a complex interplay of pop-
ulation genetic differences, including varying linkage-
disequilibrium patterns and allele-frequency differences,
between the target sample and the GWAS data can limit
generalizability across populations.10,11 Can similar prob-
lems appear also within a much more genetically and
environmentally homogeneous setting than between
populations from different continents? This is a crucial
question for the public healthcare systems in countries
that have the growing potential to implement PSs as part
of their population-wide practice.
In this work, we evaluate the geographic distribution of
the PSs of several complex diseases and traits in Finland
anddemonstratehowtheeffect of geneticpopulation struc-
tureneeds tobe assessedbeforePSs canbecomea robust tool
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Figure 1. A Comparison of Genetic Population Structure, Incidence Rates, and Distribution of the Polygenic Score of Coronary Artery
Disease in Finland
(A–C) Main genetic population structure (A), the incidence rate for age-adjusted coronary artery disease (CAD) in 2013–2015 (Sepelval-
timotauti-indeksi, see Web Resources) (B), and the distribution of the polygenic score (PS) for CAD (C) in Finland. The population struc-
ture was estimated by clustering 2,376 samples into two groups.13 The incidence rate is scaled to have a mean¼ 100. The PS distribution
is shown in units of standard deviation.
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study. First, on a world-wide scale, Finland has a demo-
graphically and socially homogeneous population and a
top-level public healthcare system,12 and these together
reduce many possible environmental effects contributing
to geographic variation in health. Second, some notable
geographic differences in phenotypes and general health
still occur in Finland. A good example is the CAD incidence
rate that is 1.6 times higher in eastern Finland than inwest-
ern Finland (Sepelvaltimotauti-indeksi, seeWeb Resources)
(Figure 1). In fact, even larger differences in CAD incidence
were observed in the 1970s, and despite the extensive and
successful public health campaign to reduce these rates
through the Northern Karelia project,14 differences be-
tween east and west still remain today. Third, the genetic
structure in Finland is well-characterized13,15–19 (Figure 1),
a factor that enables a detailed comparison between the
geographic distribution of PSs and the overall genetic
population structure within the country.
In our analyses, we observe clear geographic structure
in PS distributions for most phenotypes considered.
Furthermore, the spatial pattern is similar across the
phenotypes and resembles the population genetic east-
west division of Finland (see a comparison for CAD in
Figure 1). Although a population genetic difference can
well result in such patterns, a major goal of this work was
to thoroughly assess whether these geographic patterns
could alternatively result from some bias that emerges
when the GWAS estimates of tens of thousands of variants
are accumulated into PSs. We do this by generating many
versions of PSs with different variant-inclusion criteria
and by monitoring how the geographic structure accumu-
lates across these PSs.2 The American Journal of Human Genetics 104, 1–13, June 6, 2019To demonstrate our approach, we consider the adult
height (HG) as a model trait. In addition to HG, we apply
our approach to two additional quantitative traits, body-
mass index (BMI) and waist-hip ratio (WHR), in five dis-
eases: coronary artery disease (CAD), rheumatoid arthritis
(RA), schizophrenia (SCZ), Crohn disease (CD), and ulcer-
ative colitis (UC). The results suggest that polygenic
components of CAD, RA, SCZ, WHR, BMI, and HG show
differences along the east-west direction, whereas only
HG and WHR also show differences in the north-south di-
rection. PSs for CD and UC do not show significant
regional differences in either direction. Last, we discuss
the credibility of the observed geographic differences. In
particular, we report possible population-stratification-
related biases in PSs for CAD, WHR, BMI, and HG. Our
results raise concerns about how to reliably interpret
geographic variation in PSs even within relatively homoge-
neous populations.Material and Methods
Geographically Defined Target Data
We used data from the National FINRISK Study, which is a survey
of the Finnish adult population (aged from 25 to 74) to estimate
risk and protective factors of chronic diseases.20 The FINRISK
Study has collected several thousand samples every five years since
1972. We used data from the FINRISK Study survey of 1997 from
2,376 individuals in a geographically defined sample that was
previously described in Kerminen et al.13 The two parents of
each individual in this sample were both born within 80 km of
each other. For the genetic analyses, we used genotypes from Illu-
mina HumanCoreExome-12 BeadChip (see details in Kerminen
et al.13) and imputed genotypes as described by Ripatti et al.21
Table 1. Summary of the Background GWAS and Our Polygenic Scores
Trait Study Method GWAS Ancestry GWAS N
Finnish
Samples Filtering in PS SNPs in PS
CAD CARDIoGRAMplusC4D
(Nikpay et al., 201523)
Logistic European þ
South Asian þ
East Asian
60,801/123,504 5,825/5,639 P value, MAF, MHC,
INFO, #Cohorts
19,597
RA Okada et al., 201424 Logistic European 18,136/49,724 – P value, MAF, MHC 32,736
CD IIBDGC (Liu et al., 201525) Logistic European 5,956/14,927 – P value, MAF, MHC,
INFO, #Cohorts
21,771
UC IIBDGC (Liu et al., 201525) Logistic European 6,968/20,464 – P value, MAF, MHC,
INFO, #Cohorts
23,513
SCZa PGC (Ripke et al., 201426) Logistic European þ
East Asian
36,989/113,075 –a P value, MAF, MHC,
INFO, #Cohorts
30,311
WHR GIANT (Locke et al., 201527) Linear European 224,459 16,000 P value, MAF, MHC,
#Samples
13,727
FINRISK20 Linear Finnish 24,919 24,919 P value, MAF, MHC 43,252
BMI GIANT (Shungin et al., 201528) Linear European 322,154 23,000 P value, MAF, MHC,
#Samples
12,742
UKBB (Neale lab29) Linear White British 337,199 – P value, MAF, MHC 75,979
FINRISK20 Linear Finnish 24,919 24,919 P value, MAF, MHC 44,920
HG GIANT (Wood et al., 201430) Linear European 253,288 23,000 P value, MAF, MHC,
#Samples
27,066
UKBB (Neale lab29) Linear White British 337,199 – P value, MAF, MHC 113,079
FINRISK20 Linear Finnish 24,919 24,919 P value, MAF, MHC 50,536
For diseases, GWAS N ¼ affected individuals/controls. The filtering column describes the thresholds used as follows: p value ¼ p value < 0.05; MAF ¼Minor allele
frequency > 0.01; MHC ¼ major histocompatibility complex removed; INFO ¼ imputation quality > 0.9; #Cohorts ¼ exists in over 90% of GWAS cohorts;
#Samples ¼ exists in over 90% of GWAS samples. Other abbreviations are as follows: CAD ¼ coronary artery disease; RA ¼ rheumatoid arthritis; CD ¼ Crohn
disease; UC ¼ ulcerative colitis; SCZ ¼ schizophrenia; WHR ¼ waist-hip ratio; BMI ¼ body-mass index; and HG ¼ height.
aOur SCZ-PS excludes Finnish samples (546/2,011) from Ripke et al. In Figures S6 and S7 we show SCZ-PS, including these Finnish samples.
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We derived PSs in our target data for each disease and trait on the
basis of large international GWAS meta-analyses whose summary
statistics were publicly available. We derived all PSs by excluding
variants whose minor allele frequency (MAF) was below 1% in a
meta-analysis, whose meta-analysis p value was above 0.05, or
that resided in the major histocompatibility complex (chr 6:
25–34 Mb).22 In addition, where applicable, we filtered out
variants whose imputation quality was below 90% or variants
that had been present in less than 90% of the cohorts or samples
of the meta-analysis. We also excluded all multi-allelic variants.
Table 1 summarizes GWAS characteristics and variant filtering
for all PSs. Finally, the PSs were built by selecting independent
variants with PLINK 1.931 (see Web Resources) via the clump com-
mand with a 500 kb window radius and a 0.1 threshold for r2.
Additional GWASs for FINRISK, UK Biobank, and GIANT
FINRISK
We used Hail (see Web Resources) to run standard linear re-
gression for HG, BMI, and WHR (adjusted for BMI) in 24,919
individuals across the National FINRISK Study collections from
1992–2012. These data excluded all 2,376 target individuals.
We used sex, age, FINRISK project year, genotyping chip, and
the first ten principal components of population structure as co-
variates in the analysis. In addition, we ran a linear mixed model
for HG with BOLT-LMM v.2.332 with the same samples and
covariates.ThUK Biobank
For the UK Biobank (UKBB), we performed a linear mixed model
GWAS for HG with BOLT-LMM v2.3.32 For this analysis, we
mimicked the linear regression analysis (round 1) of the Neale
lab29 and used UKBB v2 genotypes on 343,728 samples with
white British ancestry. We used age, sex, and the first 20 prin-
cipal components as covariates, and we used directly genotyped
variants with a MAF above 1% and missingness below 10% for
generating the variance component. GWAS statistics were calcu-
lated for imputed data with a MAF above 0.1% and an imputa-
tion quality above 0.7.
GIANT
We made two additional versions of the GIANT consortium
meta-analysis with METAL,33 as in Wood et al.,30 except that
in the first version we excluded the cohorts that included sam-
ples from the National FINRISK Study (FUSION, MIGEN,
and COROGENE) and in the second version we excluded all
cohorts that included any Finnish samples (DGI, FTC, FUSION,
GENMETS, MIGEN, NFBC1966, COROGENE, FINGESTURE,
HBCS, and YFS).
Polygenic Scores
We calculated PSs for the target set of 2,376 FINRISK individuals by
using the additive model of:
PSi ¼
XM
j¼1
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Table 2. Results from the Linear Model for Correlated Data where Polygenic Score is Explained by Latitude or Longitude
Latitude Longitude
Trait SNPs Estimate P value Estimate P value WF-EF Difference (95% CI)
CAD 19,597 6.3 3 104 0.97 0.05 1.6 3 104* 0.63 (0.71, 0.55)
RA 32,736 0.03 0.12 0.06 5.5 3 105* 0.63 (0.71, 0.55)
CD 21,771 0.03 0.18 0.002 0.87 0.10 (0.01, 0.19)
UC 23,513 0.03 0.23 0.02 0.22 0.26 (0.35, 0.18)
SCZ 30,311 0.04 8.7 3 102 0.04 4.0 3 103* 0.35 (0.43, 0.26)
BMI 12,742 0.03 9.4 3 102 0.04 1.8 3 103* 0.53 (0.61, 0.44)
WHR 13,727 0.10 1.0 3 109* 0.08 4.7 3 1012* 1.16 (1.23, 1.09)
HG 27,066 0.18 1.1 3 1040* 0.15 2.1 3 1060* 1.51 (1.45, 1.58)
SNPs ¼ number of variants in PS. The difference in PS between Western Finland (WF) and Eastern Finland (EF) subpopulations is given in the standard deviation
unit of PS. * marks a p value < 0.05. Abbreviations are as follows: CI ¼ confidence interval, CAD ¼ coronary artery disease; RA ¼ rheumatoid arthritis; CD ¼ Crohn
disease; UC ¼ ulcerative colitis; SCZ ¼ schizophrenia; WHR ¼ waist-hip ratio; BMI ¼ body-mass index; and HG ¼ height.
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(imputed) genotype dosage for SNP j, and bbj is the effect size
estimate of SNP j from the GWAS.Genetic Risk Maps
To visualize the geographic distribution of PSs, we used the
geographic locations of our geographically well-defined sample
of 2,376 individuals and their PSs. We estimated an individual’s
geographic location as the mean of his or her parents’ birth-
places. We then created risk maps in R by using a geographical
centroid approach; this approach lays a grid on the map of
Finland, and for each grid point p, it calculates the average of in-
dividuals’ PSs inversely weighted by their squared distance to the
grid point as
PSp ¼ 1
rTot
XN
i¼1
PSi
r2ip
;
where rip is the distance between individual i and grid point
p and rTot ¼
P
i
1=r2ip is the sum of the weights. We used a grid
with a square size of 10 km and limited the minimum value for
rip to be 50 km to avoid high variance in weights. In addition,
to control for uncertainty in the areas that have a low sample
size, we added to the calculation of PSp one pseudo-individual
whose PS is the population average PS and whose distance to
the point p is the minimum of the observed distances rip. This
modification draws the PS values of grid points toward the popu-
lation average, especially in sparse areas where there are few
individuals at the minimum range from the grid point. Last,
the risk maps were scaled by the population average and standard
deviation with a subset of 1,042 geographically evenly distributed
individuals as described in Kerminen et al.13 The border line
for the map of Finland was obtained from GADM (see Web
Resources).A Linear Model for Correlated Data for Assessing Spatial
PS Differences
To quantify whether the PS has geographic differences, we
performed a regression analysis with a linear model for correlated4 The American Journal of Human Genetics 104, 1–13, June 6, 2019data wherein we explained PS with latitudinal or longitudinal
coordinates and accounted for genetic relatedness as
PSi¼mþ xiaþ ε ε  N

0;s2
ε
RÞ;
where xi is the coordinate of individual i, m is the intercept,
and a is the effect of latitude or longitude on PS reported in
Tables 2, S4, S6 and S7. For the structure of the error terms, we
used the genetic relationship matrix R that was estimated with
PLINK 1.931,34 (command --make-rel) with 61,598 independent
variants from the Illumina HumanCoreExome chip described
in Kerminen et al.13 Regression results from the standard linear
model without accounting for genetic relatedness are shown in
Table S1.Polygenic and Phenotypic Differences between
Subpopulations
The two main subpopulations in Finland are located in western
Finland (WF) and eastern Finland (EF); they were previously
described in Kerminen et al.13 and are shown in Figure 1A. Here,
we reproduced this analysis by using CHROMOPAINTER and
FineSTRUCTURE35 with our current sample of 2,376 individuals
to estimate both phenotypic and polygenic score differences
between these two populations. The analysis divided our target
sample into 1,604 EF and 772 WF individuals, and we used this
division for estimating the differences between subpopulations.
PS Differences in Standard Deviation Units
We calculated the PS differences between the subpopulations by
first scaling the PSs of the target sample with the subset of 1,042
geographically evenly distributed samples. We then used scaled
PSs to calculate the difference between WF and EF. This strategy
ensured a robust comparison between PSs on the basis of a fixed
reference set. The 95% confidence intervals for the difference be-
tween two groups were given by Welch’s t test in R 3.4.1.36
Phenotypic Differences Predicted by PS
For HG, BMI, and WHR, we also estimated the phenotypic differ-
ence predicted by PS between our subpopulations. First, we fitted
the linear model wherein we explained the phenotype with the
general covariates of sex, age (measured in 1997 and also repre-
sented by the birth year), and age2 (WHR was additionally
adjusted for BMI) in our target sample. Then we fitted another
Please cite this article in press as: Kerminen et al., Geographic Variation and Bias in the Polygenic Scores of Complex Diseases and Traits in
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basis of the effect estimates of the second model, we were able
to estimate the predicted phenotypic effect by multiplying the
PS effect estimate with the PS difference between the populations.
We estimated the respective 95% credible intervals by using a
simulation approach wherein we generated 100,000 sample pairs
of effect estimates for PS difference, d, and PS effect on phenotype,
b, from their sampling distributions, and we used the empirical
distribution of d*b to determine the 95% credible interval. The
sampling distribution of d was modeled as a normal distribution
with a mean set to the observed PS difference and the standard de-
viation calculated from the 95% confidence interval from the
Welch’s t test as ðx CIlowÞ=1:96. The sampling distribution of b
was modeled as a normal distribution with a mean set to the
observed effect estimate and the standard deviation set to the cor-
responding standard error from the linear model.
Observed Phenotypic Differences for HG, BMI, and WHR
We estimated the observed phenotypic differences in HG, BMI,
andWHR betweenWF and EF by adjusting the corresponding trait
for sex, age, and age2 (WHR was additionally adjusted for BMI) via
linear regression, and then we calculated the difference of the sub-
population means on the basis of the residuals from this regres-
sion. The residuals were maintained in the units of the original
phenotypes.P Value Thresholding in PSs
We studied the effect of p value threshold for our PSs by applying
seven different thresholds (p value< 13 102, 13 103, 13 104,
1 3 105, 1 3 106, 1 3 107, and 1 3 108) to the variants of
initial PSs (that used a threshold of 0.05) and calculated the addi-
tional PSs as described above.Detecting Accumulation of Biases with Weakly
Associated Variants (‘‘Random PSs’’)
To detect the accumulation of biases, we used an approach where
we first filtered the GWAS summary statistics similarly to the orig-
inal scores (as explained above), except we considered only vari-
ants with the GWAS p value > 0.5. This left us with, at most,
very weakly associated variants. Among these p > 0.5 variants,
we performed linkage disequilibrium (LD) clumping with the
same parameters as above, except we set the p value cut-off to 1
in order to not further exclude any variant on the basis of its
p value, and we permuted the p values among the p > 0.5 variants
to ensure that the resulting scores are randomwith respect to their
p value. LD clumping resulted in different numbers of variants for
different traits, and from those we randomly sampled increasing
numbers of variants (5,000, 10,000, 20,000, 40,000, 60,000, and
80,000). For BMI and WHR, the remaining number of variants af-
ter LD clumping was <80,000, and hence we were not able to
compute a PS for 80,000 for these two traits. Finally, we calculated
the PS for each individual and evaluated the difference between
subpopulations in these ‘‘random PSs.’’ To assess uncertainty, we
repeated the random PS generation ten times, and we report the
mean and the range of the subpopulation difference over these
ten random PSs.
To understand the expected behavior of PSs with truly zero
effect sizes and to compare with our observed random PSs, we
generated 1,000 simulated PSs for each observed random PS. These
PSs were simulated from the variants from the random PSs but
sampled their effect estimates independently from a normal distri-
bution with a mean of zero and a standard deviation that corre-Thsponded to the standard error of the variant in GWAS. In Figure 5,
we see that the 95% highest probability interval of the population
difference is approximately constant across the different number
of variants in the PSs and across the different GWASs. Supple-
mental Text S1 describes the theoretical basis for this property.
Our simulated 95% intervals assume completely independent
variants, whereas our PS pipeline used a more liberal LD threshold
of r2 < 0.1. Therefore, we also compared the effects of residual LD
to our random scores by performing LD clumping with r2 thresh-
olds of 0.01 and 0.001 for CAD and HG with GIANT and UKBB
data. Figure S1 shows that, for GIANT-PS, the residual LD does
not have an effect on the accumulation of population difference,
and a similar tendency is suggested for CAD-PS even though the
data are limited. For UKBB-PS, there is no accumulation of differ-
ence for any r2 threshold.
The imputation-quality filter did not noticeably affect the re-
sults from either the actual PS or the random PS (Figure S2).Results
Polygenic Scores Show Geographic Differences in
Finland
We estimated PSs across Finland by using a geographically
well-defined sample of 2,376 individuals from the National
FINRISK Study 1997 survey.20 The parents of each of these
2,376 individuals were born within 80 km of each other,
and the means of the parents’ coordinates were used as
the individuals’ locations. We derived PSs for the individ-
uals with summary statistics from publicly available
GWAS meta-analyses by applying LD pruning (r2 < 0.1),
MAF filtering (MAF > 0.01), and p value thresholding
(p < 0.05) (see Material and Methods). To visualize the re-
sults on the map of Finland (Figure 2), we estimated the
score at each map point by averaging individuals’ PSs
inversely weighted by the individuals’ squared distance
from the point (see Material and Methods).
We applied our approach to five diseases, CAD, RA, CD,
UC, and SCZ, as well as to three quantitative traits, BMI,
WHR adjusted for BMI, and HG. We observe that the PS
patterns for CAD, RA, SCZ, BMI, HG, and WHR closely
resemble the main population structure in Finland
(Figure 1A). CD and UC do not show clear geographic
differences between any parts of the country.
To evaluate statistically whether the PSs show
geographic differences, we quantified the patterns by using
a linear model for correlated data, wherein we explained
individuals’ PSs with either longitude or latitude and ac-
counted for genetic relatedness of the samples (seeMaterial
and Methods). The strongest differences were observed for
HG (p¼ 2.13 1060) andWHR (p ¼ 4.73 1012) based on
longitude, and lower but non-zero differences were
observed for CAD, RA, SCZ, and BMI (all with p < 0.05)
(Table 2, see Table S1 for results based on the standard
linear model without accounting for genetic relatedness).
HG and WHR showed differences also based on latitude,
whereas CD and UC did not show differences based on
either longitude or latitude. Table 2 also shows that the
difference in PS between WF and EF subpopulations ise American Journal of Human Genetics 104, 1–13, June 6, 2019 5
Figure 2. Distribution of Polygenic Scores in Finland
(A–H) Distribution of polygenic scores for (A) coronary artery disease, (B) rheumatoid arthritis, (C) Crohn disease, (D) ulcerative colitis,
(E) schizophrenia, (F) body-mass index, (G) waist-hip ratio adjusted for body-mass index, and (H) height. P values correspond to the
association with longitude presented in Table 2.
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general, we observed stronger PS differences between east
and west than between north and south, and this observa-
tion is in line with the main population structure in
Finland.
Recently, it has been reported that PS differences between
populations are prone to technical and confounding biases
arising especially from population genetic differences (i.e.,
genetic divergence) or relatedness structure between the
GWAS discovery and the target data.10,11,37–39 To assess
whether some of the results in Figure 2 and Table 2 might
be affected by these problems, we next concentrate on eval-
uating our PSs in several ways. We used HG as a model trait
for developing the methodology.
Height PSs in Three Independent Cohorts
Adult height (HG) is a highly heritable and polygenic
trait30,40,41 and shows clear phenotypic differences in
Finland; western Finns are on average 1.6 cm taller than
eastern Finns (see Material and Methods and Figure 3A).
Furthermore, HG is a quantitative trait that makes it
possible to compare geographic differences between the6 The American Journal of Human Genetics 104, 1–13, June 6, 2019observed phenotype and the predictions based on PS. For
such comparisons, we regressed out effects of sex, age,
and age2 fromHG by using residuals from a standard linear
model.
We calculated HG-PS by using summary statistics from
three independent GWASs, including results from the GI-
ANT consortium (a meta-analysis from a heterogeneous
set of European samples),30 the UK Biobank (a single
cohort of uniformly genotyped and phenotyped white-
British samples), and the National FINRISK study (Finnish
samples genotyped with two different chips) using our
standard pipeline (see Material andMethods). Table 3 sum-
marizes the performance of these three scores.
The GIANT consortium height GWAS is a meta-analysis
of 250,000 samples from multiple European populations,
and it includes about 23,000 Finnish samples.30 The GI-
ANT-PS included 27,000 variants, explained 14% of the
variance of height, and showed dramatic geographic differ-
ences in Finland (Figure 3B). The GIANT-PS was 1.5 SDs
larger in WF than in EF, and we estimated, by regressing
height on this PS in the target sample of 2,376 Finnish in-
dividuals, that this difference would correspond to a
Figure 3. Distributions of Adult Height and Three Polygenic Scores for Height
(A–D) A distribution of sex-, age-, and age2-adjusted adult height (A) and polygenic score (PS) distributions of GIANT-PS (B), UKBB-PS (C),
and FINRISK-PS (D) for height in Finland. The values are presented in standard deviation units.
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(see Material and Methods). This difference is over twice
the observed phenotypic difference between the subpopu-
lations. Note that even if we assumed that all variation in
height was genetic, we would expect our GIANT-PS (that
has R2 < 15%) to explain only a part of the actual 1.6 cm
WF-EF height difference. This raises concerns that in our
target sample, GIANT-PS produces geographically biased
results that cannot be interpreted directly on the pheno-
typic scale. The predicted WF-EF difference was even larger
for GIANT-PS if the HG-on-PS regression was done
within the WF subpopulation (4.7 cm) or within the EF
subpopulation (6.4 cm) alone (Table S2), indicating chal-
lenges of interpretability for absolute differences among
subpopulations.
Second, we built a PS based on over 330,000 UK Biobank
British ancestry samples analyzed by the team led by
Benjamin Neale.29 Using the same pipeline as with
GIANT-PS, this UKBB-PS contained considerably more var-
iants and gave qualitatively similar geographic results to
GIANT-PS, but quantitatively it showed much smaller
WF-EF differences (Figure 3C). UKBB-PS explained 22%
of the variation of height in the target sample and corre-
sponded to a 0.6 cm predicted WF-EF difference in height.
Third, we built a PS based on the Finnish-population-
specific summary statistics from the National FINRISK
Study.20 This FINRISK GWAS included nearly 25,000 sam-
ples and excluded all our 2,376 target individuals. This
FINRISK-PS (50,000 SNPs) explained 15% of the variance
of height and showed significant WF-EF differences
that corresponded to a 1.4 cm difference in predicted
height (Figure 3D). For FINRISK-PS and UKBB-PS, the
predictions were robust to whether the regression was
done in the whole target sample or in its WF or EF
subset alone (Table S2).
These results show a consistent direction in predicted
height differences between western and eastern Finland
on the basis of three independent GWASs that haveThdifferent relationships to the target sample. The predicted
direction is also consistent with the observed phenotypic
difference. However, the results show considerable, and
concerning, variation in the predicted geographic differ-
ence of the genetic component of height.
Evaluating Possible Biases in Polygenic Score for Height
A PS from GIANT Accumulates Geographic Differences
An accumulation of small biases might be a substantial risk
in the PSs of thousands of variants. These small biases can
arise, for example, from unadjusted population structure
in the underlying GWAS or from overlapping samples be-
tween GWAS and target data.42,43 To understand whether
the differences in our PS and the unrealistic predictions
of geographic height differences might be due to a bias
accumulation, we generated additional PSs by varying
the inclusion criteria of variants.
First, we used variants from the initial PS but applied
different p value thresholds. Even though these scores
included different numbers of variants, the variance
explained did not vary strongly across the thresholds for
GIANT-PS or UKBB-PS (Figure 4A), a finding that replicates
the behavior of PSs reported earlier by Wood et al.30 for
other target populations. For FINRISK, the variance ex-
plained increased considerably with a more liberal p value
threshold because of the smaller sample size of the study;
specifically, the FINRISK-PS included only a handful of
variants for the smallest p value thresholds, and thus had
only a little predictive power there (Figure 4A). Conversely,
the predicted east-west height differences in the GIANT-PS
decreased considerably as more stringent p value cutoffs
were used, whereas the variance in height explained by
the PS increased simultaneously (Figure 4B). The decrease
was much subtler for the other two PSs. To confirm the
effect of the number of variants on the predicted height
differences, we randomly sampled 1,000 variants from
each of the different p value thresholds in GIANT-PS and
calculated the corresponding scores. These PSs showede American Journal of Human Genetics 104, 1–13, June 6, 2019 7
Table 3. Summary of the Results in the HG-PS Comparison
Source GWAS Ancestry GWAS N
Finnish
Samples
Variants
in PS Adjusted R2
Predicted WF-EF HG
Difference (cm; 95% CI)
Observed WF-EF HG-PS
Difference (SD unit; 95% CI)
GIANT European 253,288 23,000 27,066 14% 3.52 (3.14, 3.90) 1.51 (1.45, 1.5)
GIANT NOFINNS European 230,794 0 25,660 17% 1.78 (1.53, 2.05) 0.70 (0.62, 0.79)
UK Biobank British 337,199 0 113,079 22% 0.64 (0.39, 0.89) 0.23 (0.14, 0.32)
FINRISK Finnish 24,919 24,919 50,536 15% 1.35 (1.14, 1.58) 0.59 (0.51, 0.67)
Adjusted R2 is the variance explained by the PS in the target set.
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1 cm) independent of the p value threshold, suggesting
that the number of variants is a more important factor
behind the geographic structure of GIANT-PS than the
actual phenotypic variance explained by the variants
(Figure S3).
Concerned about the accumulation ofWF-EF differences
in GIANT-PS, we tested whether similar accumulation
occurred even over random, non-associated variants. We
randomly sampled different numbers of independent var-
iants whose p values were over 0.5 in GWAS (suggesting a
negligible association to height) and calculated PSs for
them (we call these ‘‘random PSs’’). This test showed
considerable geographic differences in random PSs based
on GIANT GWAS, and these differences increased with
the number of variants (Figures 4C and 4D). Similar but
weaker behavior was detected for FINRISK variants but
not for UKBB variants.
Correlation of PS with Principal Component 1
One potential explanation for the observed behavior of
GIANT-PS is that the effect-size estimates have a consis-
tent directional bias that is aligned with the main popula-
tion structure in Finland. Indeed, GIANT-PS is highly
correlated with the leading principal component (PC1)
of population structure in our target sample (r ¼ 0.80),
and when we removed the linear effect of PC1 from the
GIANT-PS (see Material and Methods), the residuals ex-
plained more variance (19%) of height than the original
GIANT-PS (14%). This suggests that in the effect-size esti-
mates of GIANT-PS, a part of the true height association is
masked by a strong component aligned with PC1 in
Finland. For neither FINRISK-PS nor UKBB-PS did the
removal of the linear effect of PC1 improve the variance
explained in our target sample (Table S3). None of the
three PSs showed WF-EF differences after the PC1 was
regressed out (Table S3). By using the variants from GI-
ANT-PS and the effect estimates from UKBB, we observed
that the strong geographic differences in GIANT-PS are
likely driven also by the choice of the GIANT variants
and not only by a bias in the GIANT effect estimates (Sup-
plemental Text S2).
Together, these analyses suggest that the geographic
distribution of PSs based on the GIANT summary statistics
consistently exaggerates height differences between
the main Finnish subpopulations, whereas much less8 The American Journal of Human Genetics 104, 1–13, June 6, 2019confounding from population stratification is seen in
FINRISK-PS, and almost none is observed in UKBB-PS. A
few possible reasons for this bias accumulation could be
the inadequate adjustment for population structure in
GWASs37,39 or partially overlapping or related samples be-
tween GWAS samples and test data.
Effect of Sample Overlap and Population-Specific Samples
Our target data originate from the National FINRISK Study
that is not reported among the GIANT cohorts (neither
among cohorts in Lango et al.,44 nor among additional co-
horts in Wood et al.30). However, a closer look into the
cohort descriptions suggested that the COROGENE,
FUSION, andMIGEN cohorts might include some FINRISK
samples. This shows that it is not always straightforward to
keep track of where publicly accessible samples have been
used previously, and this observation would be a crucial
piece of information for appropriately validating PSs.
Although computational methods exist to detect sample
overlaps between GWAS summary statistics,45 their
behavior in large datasets is not yet completely under-
stood.46
To test whether overlapping individuals affect the results
of GIANT-PS, we built a new PS without any FINRISK
samples (called GIANT-NOFR-PS). This GIANT-NOFR-PS
explained 16% of the height variance and predicted a
3.4 cm (95% CI: 3.0–3.7) difference between WF and EF,
and this difference is very similar to the result of the
original GIANT-PS (14%, 3.5 cm [95% CI: 3.2–3.9]). Thus,
a possible sample overlap is not causing the exaggerated
WF and EF differences in GIANT-PS.
Next, we excluded the cohorts that included any Finnish
samples from the meta-analysis. This GIANT-NOFINNS-PS
explained 17% of the height variance and predicted a
1.7 cm (95% CI: 1.5–2.1) difference between WF and EF
(Figure S4). This is a significantly smaller difference than
that found by the original GIANT-PS, and a similar drop
is also seen in the bias accumulation of GIANT-NOFINNS-
PS (Figures 4 and S5). A similar but weaker effect was
detected for SCZ when comparing PSs based on meta-ana-
lyses with and without Finnish samples (see Figures S6 and
S7 and Table S4). These results suggest that although
population-specific PSs have the potential to increase pre-
diction accuracy, they might also introduce considerable
bias if the population structure has not been adjusted
properly.
A B
C D
Figure 4. A Comparison of PSs Con-
structed from Height-Associated versus
Random SNPs Demonstrates Differences
in Stratification Effects by GWAS Summary
Statistics
Top row: (A and B) Height variance ex-
plained by PS (A) and east-west difference
in height predicted by PS (B) as a function
of p value threshold in GWAS data.
Bottom row: (C and D) Height variance ex-
plained by PS (C) and east-west difference
in height predicted by PS (D) as a function
of the number of independent variants in
PS when all variants have a p value > 0.5
in GWAS (‘‘random scores’’). Variance ex-
plained is given as adjusted R2. In C
and D, the values are based on ten random
scores, and error bars in D show the range
of those scores.
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with a linear mixed model that accounts for genetic relat-
edness, the resulting PSs predicted smaller geographic dif-
ferences betweenWF and EF than our original GWAS based
on linear regression with ten PCs as covariates, but the dif-
ferences were not significant (Figure S8 and Table S5).
Bias Accumulation in Other Complex Diseases and Traits
After assessing multiple sources of bias accumulation in
HG, we applied similar strategies to the other seven pheno-
types. For each phenotype, we generated random PSs with
increasing numbers of variants to detect a possible accu-
mulation of biases. Here, we present absolute difference be-
tween western and eastern Finland using standardized PSs
because we did not have a way to turn these to the pheno-
typic scale for the disease studies. Figure 5 shows that for
RA, CD, UC, and SCZ, the absolute WF-EF PS difference
of the random score is close to zero, whereas for CAD,
BMI, WHR, and HG we observe a possible accumulation
of bias.
Similarly to HG, we were able to compare the geographic
distribution of the PSs of BMI and WHR to their pheno-
typic counterparts. Neither BMI nor WHR shows clear
geographic patterns in our data, but the PSs of BMI and
WHR largely repeat the results of the PS of HG (Figures
S9, S10, S11, and S12 and Tables S6 and S7). For both
BMI and WHR, GIANT-PS shows much larger differences
and bias accumulation in random scores between WF-EF
than FINRISK-PS (BMI and WHR) or UKBB-PS (only BMI
available).The American Journal ofDiscussion
Polygenic scores (PSs) have recently
reached predictive power for some
well-established monogenic risk fac-
tors for disease,7 and several projects
are currently testing their utility in
health care settings. PSs could also
potentially inform us about the role
of genetics in the geographic vari-ability of traits and disease. However, a major challenge
is that the geographic distribution of PSs is a complex
function of population genetic differences between the
GWAS data and the target samples, complicating its inter-
pretation.10,11,47,48 Here, we studied the geographic distri-
bution of several PSs within Finland and assessed their
robustness and possible biases in several ways.
By generating PSs for eight phenotypes in Finnish sam-
ples, we observed strong similarities between the
geographic distribution of several PSs and the main
Finnish population structure that runs from south-west
to north-east.13 We further showed that even the least sta-
tistically significantly associated half of the effect sizes
(with GWAS p value > 0.5) was carrying a consistent
pattern of east-west difference for CAD (CARDIoGRAM
data) and the three anthropometric traits from the GIANT
consortium: HG, BMI, and WHR, findings that we inter-
pret to indicate a likely bias. In theory, such a pattern could
also result from extreme polygenicity. However, with the
highly polygenic HG as our model trait, we showed that
the random score from our largest HG GWAS based on
the UK Biobank did not show any east-west variation
within Finland. This suggests that the geographic differ-
ence accumulating in the random score from GIANT is
rather due to bias than polygenicity. Furthermore, we
observed for HG that the GIANT-PS was so strongly aligned
with the first principal component of the genetic structure
in our target data that this association masked some of the
predictive power of the PS. This suggests that the effectHuman Genetics 104, 1–13, June 6, 2019 9
Figure 5. Accumulation of Geographic Differences in Random Polygenic Scores
The absolute value of PS difference between western and eastern subpopulations with different numbers of independent variants
(r2 < 0.1) randomly chosen with GWAS p value > 0.5. For BMI and WHR, the data did not contain more than 60,000 independent
variants. The solid region is the 95% probability interval under the theoretical null assumption of zero effect sizes and completely
independent variants (r2 ¼ 0) (see Material and Methods). Points show the mean, and error bars show the range over ten random
scores.
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main population structure in Finland, and this finding is
in line with two recent studies that have reported related
biases in the context of polygenic selection studies.37,39
When we removed all Finnish samples from the GIANT
meta-analysis of HG, the east-west difference in PS was
halved, but still remained threefold compared to that in
UKBB-PS. Also, the random scores showed that although
a considerable proportion of the bias in GIANT-PS was
related to the Finnish GWAS samples, a considerable bias
still remained after excluding the Finnish samples.
For all three quantitative traits, PSs predicted unrealisti-
cally large geographic differences compared to the actual
phenotypic differences. A theoretical but unlikely possibil-
ity remains that the geographic structure of the genetic
component not explained by our current PSs could be
opposite to the component that is explained by our
current PSs, and this could eventually balance out the un-
realistically large estimates for GIANT-PS and FINRISK-PS.
However, given that the estimated difference consistently
increases with the inclusion of more variants in PSs, a
more plausible explanation is that we simply cannot
robustly interpret the geographic differences in PSs derived
from existing GWASs on the phenotypic scale via a simple
regression framework. Earlier, the results of phenotypically
inconsistent PS differences between continental groups
have been reported.10,11,38 Here, we show that similar
patterns can exist even for a relatively small geographic
area and the relatively homogeneous population of
Finland. We note that even if the genetic EF-WF difference
in Finland might be large compared to variation within
some other European countries,19 it is tiny compared to
the continental differences.4910 The American Journal of Human Genetics 104, 1–13, June 6, 2019Our results showed that the phenotypes that did not
accumulate EF-WF differences were the two types of in-
flammatory bowel disease (CD and UC), SCZ, and RA.
Of these, CD and UC did not show any geographic PS
variation in Finland. To our knowledge, only two studies
have studied the geographic variation in the prevalence
of inflammatory bowel disease (IBD) in Finland.
Lehtinen et al.50 reported higher incidence rates of pedi-
atric IBD in more sparsely populated areas, whereas
Jussila et al.51 reported increasing prevalence rates of
UC in Northern Finland but no geographic structure
for CD. Our polygenic risk prediction for CD is in line
with the observations in Jussila et al.,51 and even
though the PS of UC did not show significant
geographic differences in our statistical analysis, the
genetic risk map for UC shows some increasing risk
pattern in Northern Finland. SCZ showed a higher poly-
genic risk in EF than in WF, a finding in line with exten-
sive geographic incidence information from several
studies52–57 that describe the highest SCZ prevalence
and incidence rates in northern and eastern Finland
and the lowest rates in the southwestern parts of the
country. Also, RA showed higher polygenic risk in EF
than in WF. Our limited information about the regional
incidence of RA in Finland is from Kaipiainen-Seppa¨nen
et al.,58 who reported the highest RA incidence rates for
North Karelia (in EF) and the lowest for Ostrobothnia
(on the west coast), but unfortunately the study did
not include southwestern or northern Finland. Neither
our SCZ nor our RA GWAS summary statistics included
any Finnish samples. Together these two diseases exem-
plify the potential of PSs to explain geographic health
differences.
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Finland, The American Journal of Human Genetics (2019), https://doi.org/10.1016/j.ajhg.2019.05.001To conclude, we recommend the following practices
for geographic evaluation of PSs. (1) Check residual
geographic stratification of PSs by generating random
scores for non-associated variants and by testing whether
PSs unrealistically strongly align with the leading PCs of
genetic structure. (2) Use a linear/logistic mixed model
instead of the standard linear/logistic regression model in
GWAS. (3) Compare the genetically predicted phenotypic
difference between populations to the observed pheno-
typic difference in order to detect unrealistic genetic
predictions. With these tools, we showed that although
PSs for several traits in Finland followed the geographic
distribution of the phenotype (HG, CAD, SCZ, RA, CD,
and UC), for CAD and HG, as well as for BMI and WHR,
we observed in the geographic distribution of PSs suspi-
cious behavior that could indicate a bias arising from
population genetic structure rather than from a direct
genotype-phenotype association. Our results emphasize
that we have limited understanding of the interplay
between our current PSs and genetic population structure
even within one of the most thoroughly studied po-
pulations in human genetics. Therefore, we recommend
refraining from using the current PSs to argue for a signif-
icant polygenic basis for geographic phenotype differences
until we understand better the source and extent of the
geographic bias in the current PSs.Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
1016/j.ajhg.2019.05.001.Acknowledgments
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